跳至主要内容
临床试验/NCT01448382
NCT01448382终止1 期

Evaluation of PillCam With Blood-Sensing Feature: A Feasibility Study

Medtronic - MITG1 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2011年10月最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
终止
入组人数
39
试验地点
1
主要终点
Agreement level between the blood detectors head to capsule video head in detecting subjects with blood in the GI tract

研究概览

简要总结

  1. Primary Scientific Objective
  • Collect human clinical data to sustain the development of blood detection sensor and optimize its algorithm and parameters
  • Preliminary evaluation of blood detection performances in human.
  1. Secondary Scientific Objective
  • Assessment of blood detection sensor ability to identify the anatomical location (i.e. Stomach, SB or Colon)
  • Evaluation of capsule transit characteristics in the GI tract
  • Evaluation of BBC capsule safety

Study Hypothesis:

It is estimated that by implementing a spectrophotometer technology in capsule and utilizing the unique characteristics of light absorption by blood in specific spectrum, the capsule will be able to automatically detect blood in the GI tract with high accuracy. As such, the system may be an add-on to video capsules to provide efficient and quick detection of blood presence (for example in OGBI patients) or as stand alone low cost capsule (without video) which could serve as a tool similar to standard FOBT.

详细描述

This study is designed to support the development of a novel blood sensing detector embedded in a PillCam® capsule and to provide initial evaluation of its performance in humans. The device is named Blood Sensing Capsule (BSC), and is based on the Given PillCam® Platform with a modified capsule.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Group A (Healthy subjects)
  • Subject's age is 18 to 45 years old
  • Subject is an healthy volunteer
  • Subject agrees to sign the Informed Consent Form
  • Group B (Symptomatic Patients)
  • Age ≥ 18 years
  • The subject was referred to Gastroscopy for at least one of the following reasons:
  • History of acute, overt UGI hemorrhage, defined as hematemesis (fresh blood or coffee grounds) and/or melena within the 48 hours prior to patient presentation
  • Subject has ongoing overt gastrointestinal bleeding with hematochezia or melena
  • Subject has Iron Deficiency Anemia ,FOBT(+) and negative colonoscopy examination
  • Other known or suspected cause of acute upper GI bleeding
  • Subject agrees to sign the Informed Consent Form

排除标准

  • Subject has Dysphagia, odynophagia, known swallowing disorder or history of Zencker's diverticulum
  • Subject is known or is suspected to suffer from bowel obstruction or bowel perforation at the time of presentation
  • Subject has history of prior bowel obstruction
  • Subject suffers UGI hemorrhage with hemodynamic shock requiring urgent endoscopy
  • Subject with any condition believed to have an increased risk for capsule retention such as Crohn's disease, intestinal tumors, radiation enteritis, incomplete colonoscopies due to obstructions or NSAID enteropathy
  • Subject has history of UGI tract surgery (e.g., Billroth I, Billroth II, esophagectomy, gastrectomy, bariatric procedure)
  • Pregnancy or nursing mothers
  • Subject has known allergy to conscious sedation medications
  • Presence of an electro-medical device (pacemaker or internal cardiac defibrillator)
  • Subject has altered mental status (e.g., hepatic encephalopathy) that would limit patient ability in swallowing the capsule
  • Known allergy to erythromycin
  • Subject is currently or within previous 30 days participating in another clinical study that may directly or indirectly affect the results of this study
  • Subject is not able to provide written informed consent.

研究组 & 干预措施

Healthy volunteers

Experimental

healthy volunteers

干预措施: PillCam® capsule with Given PillCam® Platform (Device)

GI bleeding subjcets

Experimental

Symptomatic patients referred to undergo standard Gastroscopy (EGD) as part of their standard medical care

干预措施: PillCam® capsule with Given PillCam® Platform (Device)

结局指标

主要结局

Agreement level between the blood detectors head to capsule video head in detecting subjects with blood in the GI tract

时间窗: 1 year

次要结局

  • Agreement level between the blood detectors head to capsule video head in detecting subjects with blood per anatomical location (i.e. stomach, small bowel or colon)(1 year)
  • Number, type and severity of adverse events(1 year)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Evaluation of PillCam With Blood-Sensing Feature: A... | 临床试验